Belvedere Trading LLC Tcr2 Therapeutics Inc. Transaction History

Belvedere Trading LLC

  • $74.4 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$0.83 - $1.44 $13,011 - $22,573
15,676 Added 96.08%
31,992 $31,000
Q3 2022

Oct 26, 2022
BUY
$1.86 - $3.75 $30,347 - $61,185
16,316 New
16,316 $26,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Belvedere Trading LLC Portfolio

Follow Belvedere Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Belvedere Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Belvedere Trading LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email